Galectin Therapeutics (GALT) Misses Q2 EPS by 1c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Nike (NKE) PT Lowered to $72 at Bernstein SocGen Group
• Trump's annual disclosures show $236 million in crypto proceeds, gifts worth $370,000